ArticleIndian pediatrics2021
Clinical Profile and Outcome of COVID-19 Among Immunocompromised Children.
Article in Indian pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of immunocompromise on outcomes of COVID-19 in children and young people-a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Critical Evaluation of the Impact of COVID-19 Pandemic on Child Health and Wellbeing and Suggested Preparedness for Future Pandemics-A Narrative Review.Health science reports · 2026Article
- Long COVID or Post-Acute Sequelae of COVID-19 (PASC) in Children and Adolescents.Clinical medicine & research · 2024Observational
- Progress in the Diagnosis and Treatment of COVID-19 in Children: A Review.International journal of general medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective study describes the clinical profile, risk of infection and outcome of coronavirus disease-19 in immuno-compromised children. It was found that children on immuno-suppressant medication has 2.89 times increased risk of infection (P=0.01). Disease manifestation was asymptomatic (P=0.01) or mild with predominant gastrointestinal symptoms (P=0.02) without alteration in immunosuppressive treatment regime.
Indexed as
Identifiers
34315835PMC8339160What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.